Answers are grounded in this paper and cite their sources.
The mammalian target of rapamycin (mTOR) is a key protein kinase controlling cellular metabolism and growth. It is part of the two structurally and functionally distinct multiprotein complexes mTORC1 and mTORC2. Dysregulation of mTOR occurs in diabetes, cancer and neurological disease. We report the architecture of human mTORC2 at intermediate resolution, revealing a conserved binding site for accessory proteins on mTOR and explaining the structural basis for the rapamycin insensitivity of the complex.
No takes yet. Share an insight, caveat, or question.
Stuttfeld et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: